Inlyta revenue

In the first nine months of this year, Pfizer’s (PFE) Inlyta revenue grew ~12% YoY (year-over-year) to $226.0 million from $256.0 million. US Inlyta sales fell ~7% YoY to $88.0 million, while international Inlyta sales fell ~14% YoY to $138.0 million. Internationally, Inlyta operations declined ~16% YoY. In the third quarter, Inlyta revenue fell ~15% YoY to $71.0 million, with US and international Inlyta sales falling ~10% and ~18% YoY to $27.0 million and $44.0 million, respectively.

Pfizer’s Inlyta and Recent Developments in Its Oncology Business

Recent developments

In September, the FDA approved Pfizer’s Vizimpro as a first-line treatment of metastatic non-small cell lung cancer with an exon-19 deletion or exon-21-L858R substitution. The ARCHER 1050 trial demonstrated Vizimpro’s safety and efficacy.

Also, in October, the FDA approved Pfizer’s Talzenna (talazoparib) for treating adults with deleterious germline BRCA-mutated human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer. The new FDA approvals are set to strengthen Pfizer’s oncology portfolio, which could significantly boost the company’s revenue growth and the iShares US Pharmaceuticals ETF (IHE), of which Pfizer comprises ~10.21%.

Latest articles

On Tuesday, Tesla (TSLA) cut the prices of its vehicles to standardize its global car line-up, according to Reuters.

Yesterday, PayPal (PYPL) announced that it would expand Xoom, which is its international money transfer service, to 32 markets in Europe.

Visa stock has risen about 37% and has outperformed the S&P 500 Index so far in 2019.

16 Jul

What to Expect from Skechers’s Q2 Results

WRITTEN BY Sharon Bailey

Skechers (SKX) is set to declare its results for the second quarter after the markets close on July 18. Here's what you should know.

On Tuesday, Canadian Pacific Railway (CP) reported strong second-quarter earnings. The company's top and bottom lines touched a record mark.

16 Jul

What to Expect from Crown Castle's Q2 Results

WRITTEN BY Sushree Mohanty

Crown Castle International (CCI) is scheduled to announce its second-quarter earnings results on Wednesday after the market closes.